Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 95 articles: HTML format

Single Articles

October 2024
1. COLLIER KA, Stover DG
   Confirmation of large BRCA2 reversion deletions leading to reconstituted in-frame transcripts detected via circulating tumor DNA.
   Ann Oncol. 2024;35:917-919.
   PubMed    
   
   
   September 2024
2. SAKAI H, Tsurutani J, Ozaki Y, Ishiguro H, et al
   A randomized, double-blind, placebo-controlled phase II study of olanzapine based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtec
   Ann Oncol. 2024 Sep 5:S0923-7534(24)03995-4. doi: 10.1016/j.annonc.2024.
   PubMed     Abstract available
   
   
   
3. ANDRE F, Cortes J, Curigliano G, Modi S, et al
   A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases.
   Ann Oncol. 2024 Sep 4:S0923-7534(24)03928-0. doi: 10.1016/j.annonc.2024.08.2347.
   PubMed     Abstract available
   
   
   
4. DE SANCTIS R, Bruzzi P, Zambelli A
   Unlocking Methodological Insights on Oncology Efficacy Endpoints: from Statistical to Clinical and Vice Versa. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer
   Ann Oncol. 2024 Sep 3:S0923-7534(24)03925-5. doi: 10.1016/j.annonc.2024.08.2345.
   PubMed    
   
   
   August 2024
5. DI MEGLIO A, Havas J, Pagliuca M, Franzoi MA, et al
   A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance two years later.
   Ann Oncol. 2024 Aug 2:S0923-7534(24)01517-5. doi: 10.1016/j.annonc.2024.
   PubMed     Abstract available
   
   
   
6. LOBO-MARTINS S, Agostinetto E, de Azambuja E, Gebhart G, et al
   Tumour Heterogeneity in Molecular Imaging for Breast Cancer.
   Ann Oncol. 2024 Aug 2:S0923-7534(24)01515-1. doi: 10.1016/j.annonc.2024.
   PubMed    
   
   
   
7. SANCHEZ-BAYONA R, Oliveira M
   Overall survival in first-line HR+/HER2- advanced breast cancer in the era of CDK4/6 inhibitors.
   Ann Oncol. 2024;35:689-691.
   PubMed    
   
   
   
8. MIGLIACCIO I, Biganzoli L, Malorni L
   The new oral SERDs in endocrine-resistant breast cancer: who will benefit the most?
   Ann Oncol. 2024;35:683-685.
   PubMed    
   
   
   July 2024
9. ROWLANDS CF, Allen S, Balmana J, Domchek SM, et al
   Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing.
   Ann Oncol. 2024 Jul 8:S0923-7534(24)01014-7. doi: 10.1016/j.annonc.2024.
   PubMed     Abstract available
   
   
   
10. FREEDMAN RA, Heiling HM, Li T, Trapani D, et al
    Neratinib and Ado-Trastuzumab-Emtansine for Pre-treated and Untreated HER2-positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium Trial 022.
    Ann Oncol. 2024 Jul 6:S0923-7534(24)01015-9. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
11. TARANTINO P, Tolaney SM
    Challenging immune exhaustion in early recurrent triple-negative breast cancer: pitfalls and hopes.
    Ann Oncol. 2024;35:579-581.
    PubMed    
    
    
    June 2024
12. ARECCO L, Bruzzone M, Bas R, Kim HJ, et al
    Impact of Hormone Receptor Status and Tumor Subtypes of Breast Cancer in Young BRCA Carriers.
    Ann Oncol. 2024 Jun 20:S0923-7534(24)00740-3. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
13. SHERRY AD, Lin TA, McCaw ZR, Ludmir EB, et al
    Interpretation of long-term survival data from MONARCH 3. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3' by M.
    Ann Oncol. 2024 Jun 3:S0923-7534(24)00718-X. doi: 10.1016/j.annonc.2024.
    PubMed    
    
    
    
14. ORLANDI A, Mastrantoni L, Bria E, Tortora G, et al
    To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall
    Ann Oncol. 2024 Jun 3:S0923-7534(24)00719-1. doi: 10.1016/j.annonc.2024.
    PubMed    
    
    
    May 2024
15. HAMILTON E, Oliveira M, Turner N, Garcia-Corbacho J, et al
    A Phase 1 dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.
    Ann Oncol. 2024 May 8:S0923-7534(24)00138-8. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
16. GOETZ MP, Toi M, Huober J, Sohn J, et al
    Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3.
    Ann Oncol. 2024 May 8:S0923-7534(24)00139-X. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
17. DENT R, Andre F, Goncalves A, Martin M, et al
    IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer.
    Ann Oncol. 2024 May 7:S0923-7534(24)00107-8. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
18. PUSZTAI L, Denkert C, O'Shaughnessy J, Cortes J, et al
    Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.
    Ann Oncol. 2024;35:429-436.
    PubMed     Abstract available
    
    
    April 2024
19. PETERS S, Loi S, Andre F, Chandarlapaty S, et al
    Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions - a position statement from the ETOP IBCSG Partners Foundation.
    Ann Oncol. 2024 Apr 20:S0923-7534(24)00108-X. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    March 2024
20. AGOSTINETTO E, Buisseret L, Salgado R, Kok M, et al
    Residual disease post neoadjuvant chemo-immunotherapy in early triple-negative breast cancer: Does it help tailor adjuvant treatment?
    Ann Oncol. 2024 Mar 12:S0923-7534(24)00077-2. doi: 10.1016/j.annonc.2024.
    PubMed    
    
    
    February 2024
21. GENNARI A, Brain E, De Censi A, Nanni O, et al
    Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): Pilot study with 18F-Fluoroestradiol (18F-FES) CT/PET.
    Ann Oncol. 2024 Feb 27:S0923-7534(24)00057-7. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    January 2024
22. HARVEY-JONES E, Raghunandan M, Robbez-Masson L, Magraner-Pardo L, et al
    Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor resistant advanced breast cancer.
    Ann Oncol. 2024 Jan 18:S0923-7534(24)00010-3. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    December 2023
23. SAURA C, Modi S, Krop I, Park YH, et al
    Trastuzumab Deruxtecan in Previously Treated Patients With HER2-Positive Metastatic Breast Cancer: Updated Survival Results From a Phase 2 Trial (DESTINY-Breast01).
    Ann Oncol. 2023 Dec 11:S0923-7534(23)05108-6. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
24. SPRING LM, Tolaney SM, Fell G, Bossuyt V, et al
    Response-guided neoadjuvant sacituzumab govitecan for localized triple negative breast cancer: results from the NeoSTAR trial.
    Ann Oncol. 2023 Dec 11:S0923-7534(23)05107-4. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
25. LOIBL S, Andre F, Bachelot T, Barrios CH, et al
    Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up(dagger).
    Ann Oncol. 2023 Dec 8:S0923-7534(23)05104-9. doi: 10.1016/j.annonc.2023.
    PubMed    
    
    
    
26. GOETZ MP, Bagegni NA, Batist G, Brufsky A, et al
    Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.
    Ann Oncol. 2023;34:1141-1151.
    PubMed     Abstract available
    
    
    
27. DAMODARAN S, O'Sullivan CC, Elkhanany A, Anderson IC, et al
    Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.
    Ann Oncol. 2023;34:1131-1140.
    PubMed     Abstract available
    
    
    
28. WANDER SA
    The ELAINE trials and the future of personalized therapy for hormone-receptor positive metastatic breast cancer.
    Ann Oncol. 2023;34:1071-1073.
    PubMed    
    
    
    
29. FULTON-WARD T, Middleton G
    The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review.
    Ann Oncol. 2023;34:1113-1130.
    PubMed     Abstract available
    
    
    November 2023
30. GIORDANO A, Lin NU, Tolaney SM, Mayer EL, et al
    Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer?
    Ann Oncol. 2023 Nov 10:S0923-7534(23)05062-7. doi: 10.1016/j.annonc.2023.
    PubMed    
    
    
    
31. AGOSTINETTO E, Ignatiadis M
    ctDNA as a predictive biomarker in advanced breast cancer: Lessons from the MONALEESA studies.
    Ann Oncol. 2023;34:955-959.
    PubMed    
    
    
    
32. UZUNPARMAK B, Haymaker C, Raso G, Masciari S, et al
    HER2-low expression in patients with advanced or metastatic solid tumors.
    Ann Oncol. 2023;34:1035-1046.
    PubMed     Abstract available
    
    
    October 2023
33. SESSA C, Paluch-Shimon S
    Reply to the Letter to the Editor 'There is no place for ovarian cancer screening in hereditary breast-ovarian cancer syndromes (in regard to "ESMO Clinical Practice Guideline on risk reduction and screening of cancer in hereditary breast-ovarian canc
    Ann Oncol. 2023 Oct 26:S0923-7534(23)04325-9. doi: 10.1016/j.annonc.2023.
    PubMed    
    
    
    
34. WONG NZH, Yap DWT, Ong RJM, Zhao JJ, et al
    Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups.
    Ann Oncol. 2023 Oct 21:S0923-7534(23)04328-4. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
35. THOMAS A, Shatsky R, Kalinsky K
    Moving Precision Forward: Extending Next Generation Sequencing to Operable Disease in Less Common Breast Cancer Subtypes.
    Ann Oncol. 2023 Oct 21:S0923-7534(23)04333-8. doi: 10.1016/j.annonc.2023.
    PubMed    
    
    
    
36. TJALMA WAA
    There is no place for ovarian cancer screening in hereditary breast-ovarian cancer syndromes.
    Ann Oncol. 2023 Oct 20:S0923-7534(23)04324-7. doi: 10.1016/j.annonc.2023.
    PubMed    
    
    
    September 2023
37. CURIGLIANO G, Burstein HJ, Gnant M, Loibl S, et al
    Understanding breast cancer complexity to improve patient outcomes: The St. Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023.
    Ann Oncol. 2023 Sep 6:S0923-7534(23)00835-9. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
38. ANDRE F, Su F, Solovieff N, Hortobagyi G, et al
    Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials.
    Ann Oncol. 2023 Sep 4:S0923-7534(23)00826-8. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    August 2023
39. PARSONS HA, Blewett T, Chu X, Sridhar S, et al
    Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
    Ann Oncol. 2023 Aug 17:S0923-7534(23)00801-3. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
40. JHAVERI K, Eli LD, Wildiers H, Hurvitz SA, et al
    Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
    Ann Oncol. 2023 Aug 17:S0923-7534(23)00800-1. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
41. LOIBL S, Azim HA Jr, Bachelot T, Berveiller P, et al
    ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC).
    Ann Oncol. 2023 Aug 9:S0923-7534(23)00798-6. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
42. OLIVIER T, Prasad V
    Costs per event averted in the neoadjuvant and adjuvant settings of early triple-negative breast cancer.
    Ann Oncol. 2023;34:723-724.
    PubMed    
    
    
    July 2023
43. TARANTINO P, Tolaney SM, Curigliano G
    Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment.
    Ann Oncol. 2023 Jul 25:S0923-7534(23)00767-6. doi: 10.1016/j.annonc.2023.
    PubMed    
    
    
    
44. WEI T, Wang D, Yuan P
    The role of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment.
    Ann Oncol. 2023 Jul 25:S0923-7534(23)00768-8. doi: 10.1016/j.annonc.2023.
    PubMed    
    
    
    
45. MOSELE F, Di Maio M
    Trastuzumab deruxtecan for breast cancer: do patients experience a comprehensive benefit?
    Ann Oncol. 2023;34:567-568.
    PubMed    
    
    
    June 2023
46. VILLACAMPA G, Tung NM, Pernas S, Pare L, et al
    Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.
    Ann Oncol. 2023 Jun 9:S0923-7534(23)00721-4. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
47. TARANTINO P, Viale G, Press MF, Hu X, et al
    ESMO Expert Consensus Statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.
    Ann Oncol. 2023 Jun 1:S0923-7534(23)00693-2. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    May 2023
48. OLIVEIRA M, Falato C, Cejalvo JM, Vila MM, et al
    Patritumab Deruxtecan in Untreated Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Final Results from Part A of the Window-of-Opportunity SOLTI TOT-HER3 Pre-Operative Study.
    Ann Oncol. 2023 May 19:S0923-7534(23)00685-3. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
49. HARBECK N, Fasching PA, Wurstlein R, Degenhardt T, et al
    Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: Primary outcome analysis of the multicenter randomized A
    Ann Oncol. 2023 May 16:S0923-7534(23)00684-1. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
50. CURIGLIANO G, Dunton K, Rosenlund M, Janek M, et al
    Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase 3 DESTINY-Breast03 study.
    Ann Oncol. 2023 May 11:S0923-7534(23)00677-4. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
51. LIPSYC-SHARF M, Tolaney SM
    Elacestrant: who are optimal candidates for the first oral SERD?
    Ann Oncol. 2023;34:449-451.
    PubMed    
    
    
    April 2023
52. GLUZ O, Kuemmel S, Nitz U, Braun M, et al
    Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial.
    Ann Oncol. 2023 Apr 14:S0923-7534(23)00136-9. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    March 2023
53. KWAPISZ D, Verret B, Garcia C, Andre F, et al
    Excellent response to olaparib in metastatic HR-positive, HER2-negative breast cancer with BRIP1 mutation.
    Ann Oncol. 2023;34:315-318.
    PubMed    
    
    
    January 2023
54. LUEN SJ, Viale G, Nik-Zainal S, Savas P, et al
    Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
    Ann Oncol. 2023 Jan 25:S0923-7534(23)00047-9. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
55. REICHERT ZR, Morgan TM, Li G, Castellanos E, et al
    Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study.
    Ann Oncol. 2023;34:111-120.
    PubMed     Abstract available
    
    
    December 2022
56. CURIGLIANO G, Mueller V, Borges V, Hamilton E, et al
    Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 3
    Ann Oncol. 2022 Dec 21:S0923-7534(22)04773-1. doi: 10.1016/j.annonc.2022.
    PubMed    
    
    
    
57. VAN BAELEN K, Geukens T, Maetens M, Tjan-Heijnen V, et al
    Corrigendum to "Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer": [Annals of Oncology 33 (2022) 769-785].
    Ann Oncol. 2022 Dec 16:S0923-7534(22)04746-9. doi: 10.1016/j.annonc.2022.
    PubMed    
    
    
    
58. LOVEDAY C, Garrett A, Law P, Hanks S, et al
    Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes.
    Ann Oncol. 2022;33:1318-1327.
    PubMed     Abstract available
    
    
    November 2022
59. TURNER NC, Swift C, Jenkins B, Kilburn L, et al
    Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate and high-risk early stage triple negative breast cancer.
    Ann Oncol. 2022 Nov 21:S0923-7534(22)04735-4. doi: 10.1016/j.annonc.2022.
    PubMed     Abstract available
    
    
    
60. BIANCHINI G, Licata L, Viale G, Gianni L, et al
    Neoadjuvant immunotherapy in triple-negative breast cancer: lesson learnt, remaining questions.
    Ann Oncol. 2022;33:1091-1093.
    PubMed    
    
    
    
61. AUGUSTIN JE, Soussan P, Bass AJ
    Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma.
    Ann Oncol. 2022;33:1134-1148.
    PubMed     Abstract available
    
    
    October 2022
62. SESSA C, Balmana J, Bober SL, Cardoso MJ, et al
    Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
    Ann Oncol. 2022 Oct 19. pii: S0923-7534(22)04193.
    PubMed    
    
    
    
63. GEYER CE JR, Garber JE, Gelber RD, Yothers G, et al
    Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer.
    Ann Oncol. 2022 Oct 10. pii: S0923-7534(22)04165.
    PubMed     Abstract available
    
    
    August 2022
64. LOIBL S, Schneeweiss A, Huober J, Braun M, et al
    Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.
    Ann Oncol. 2022 Aug 9. pii: S0923-7534(22)03791.
    PubMed     Abstract available
    
    
    
65. PALUCH-SHIMON S, Cardoso F, Partridge AH, Abulkhair O, et al
    ESO-ESMO 5(th) International Consensus Guidelines for Breast Cancer in Young Women (BCY5).
    Ann Oncol. 2022 Aug 4. pii: S0923-7534(22)01858.
    PubMed     Abstract available
    
    
    June 2022
66. DING K, Chen F, Priedigkeit N, Brown DD, et al
    Single cell heterogeneity and evolution of breast cancer bone metastasis and organoids reveals therapeutic targets for precision medicine.
    Ann Oncol. 2022 Jun 25. pii: S0923-7534(22)01734.
    PubMed    
    
    
    May 2022
67. VAN BAELEN K, Geukens T, Maetens M, Tjan-Heijnen V, et al
    Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.
    Ann Oncol. 2022 May 20. pii: S0923-7534(22)01167.
    PubMed     Abstract available
    
    
    
68. LOIBL S, Untch M, Burchardi N, Huober J, et al
    Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Onco
    Ann Oncol. 2022 May 17. pii: S0923-7534(22)00676.
    PubMed    
    
    
    
69. MARCZYK M, Mrukwa A, Yau C, Wolf D, et al
    Treatment Efficacy Score - continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
    Ann Oncol. 2022 May 2. pii: S0923-7534(22)00762.
    PubMed     Abstract available
    
    
    April 2022
70. TARANTINO P, Jin Q, Mittendorf EA, King TA, et al
    Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib.
    Ann Oncol. 2022 Apr 28. pii: S0923-7534(22)00754.
    PubMed    
    
    
    
71. PICCART MJ, Kalinsky K, Gray R, Barlow WE, et al
    Erratum to "Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust": [Annals of Oncology 32 (2021) 1077-1082].
    Ann Oncol. 2022 Apr 26. pii: S0923-7534(22)00673.
    PubMed    
    
    
    
72. GEYER CE, Sikov WM, Loibl S
    Reply to the Letter to the Editor "Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple negative breast cancer" by A. Okines and N. Turner.
    Ann Oncol. 2022 Apr 4. pii: S0923-7534(22)00671.
    PubMed    
    
    
    March 2022
73. RUGO HS, O'Shaughnessy J, Boyle F, Toi M, et al
    Adjuvant Abemaciclib Combined with Endocrine Therapy for High Risk Early Breast Cancer: Safety and Patient-Reported Outcomes From the monarchE Study.
    Ann Oncol. 2022 Mar 22. pii: S0923-7534(22)00383.
    PubMed     Abstract available
    
    
    
74. TOMASIK B, Bienkowski M, Jassem J
    Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the die has not been cast.
    Ann Oncol. 2022 Mar 16. pii: S0923-7534(22)00384.
    PubMed    
    
    
    
75. FLEMING GF, Pagani O, Regan MM, Walley BA, et al
    Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
    Ann Oncol. 2022 Mar 14. pii: S0923-7534(22)00380.
    PubMed    
    
    
    
76. OKINES A, Turner N
    Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple negative breast cancer.
    Ann Oncol. 2022 Mar 14. pii: S0923-7534(22)00364.
    PubMed    
    
    
    
77. ZANELLI S, Fiorio E, Zampiva I, Zacchi F, et al
    Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona.
    Ann Oncol. 2022 Mar 8. pii: S0923-7534(22)00363.
    PubMed    
    
    
    February 2022
78. GIANNI L, Huang CS, Egle D, Bermejo B, et al
    Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study.
    Ann Oncol. 2022 Feb 16. pii: S0923-7534(22)00113.
    PubMed     Abstract available
    
    
    January 2022
79. GEYER CE JR, Sikov WM, Huober J, Rugo HS, et al
    Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial.
    Ann Oncol. 2022 Jan 27. pii: S0923-7534(22)00018.
    PubMed     Abstract available
    
    
    
80. DALMARTELLO M, La Vecchia C, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2022 with focus on ovarian cancer.
    Ann Oncol. 2022 Jan 13. pii: S0923-7534(21)04881.
    PubMed     Abstract available
    
    
    
81. GAO JJ, Krol D, Narayan P, Cardoso F, et al
    Corrigendum to "Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria": [Annals of Oncology 32 (2021) 950-953].
    Ann Oncol. 2022 Jan 7. pii: S0923-7534(22)00002.
    PubMed    
    
    
    
82. NITZ UA, Gluz O, Christgen M, Grischke EM, et al
    Corrigendum to "De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertu
    Ann Oncol. 2022 Jan 7. pii: S0923-7534(21)04883.
    PubMed    
    
    
    December 2021
83. CURIGLIANO G, Mueller V, Borges V, Hamilton E, et al
    Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis.
    Ann Oncol. 2021 Dec 22. pii: S0923-7534(21)04879.
    PubMed     Abstract available
    
    
    
84. TARANTINO P, Burstein HJ, Lin NU, Krop IE, et al
    Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
    Ann Oncol. 2021 Dec 20. pii: S0923-7534(21)04877.
    PubMed    
    
    
    
85. SPRING L, Matikas A, Bardia A, Foukakis T, et al
    Adjuvant abemaciclib for high-risk breast cancer: the story continues.
    Ann Oncol. 2021;32:1457-1459.
    PubMed    
    
    
    November 2021
86. CARDOZO JMNL, Byng D, Drukker CA, Schmidt MK, et al
    Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04829.
    PubMed     Abstract available
    
    
    
87. POGGIO F, Tagliamento M, Ceppi M, Bruzzone M, et al
    Adding a platinum agent to neoadjuvant chemotherapy for triple negative breast cancer: the end of the debate.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04831.
    PubMed    
    
    
    
88. HAN HS, Arun BK, Kaufman B, Wildiers H, et al
    Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04833.
    PubMed     Abstract available
    
    
    
89. EMENS LA, Adams S, Barrios CH, Dieras V, et al
    Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993.
    Ann Oncol. 2021 Nov 2. pii: S0923-7534(21)04520.
    PubMed    
    
    
    October 2021
90. HARBECK N, Rastogi P, Shahir A, Johnston S, et al
    Letter to the Editor for "Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study".
    Ann Oncol. 2021 Oct 28. pii: S0923-7534(21)04551.
    PubMed    
    
    
    
91. FUENTES-ANTRAS J, Cescon DW
    PARP inhibitor sensitivity in BRCA-related metastatic breast cancer: an OlympiAD later.
    Ann Oncol. 2021 Oct 19. pii: S0923-7534(21)04523.
    PubMed    
    
    
    
92. GENNARI A, Andre F, Barrios CH, Cortes J, et al
    ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.
    Ann Oncol. 2021 Oct 13. pii: S0923-7534(21)04498.
    PubMed    
    
    
    
93. HE W, Eriksson M, Eliasson E, Grassmann F, et al
    CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.
    Ann Oncol. 2021;32:1286-1293.
    PubMed     Abstract available
    
    
    September 2021
94. HARBECK N, Rastogi P, Martin M, Tolaney SM, et al
    Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study.
    Ann Oncol. 2021 Sep 29. pii: S0923-7534(21)04494.
    PubMed     Abstract available
    
    
    
95. WANG Y, Acs B, Robertson S, Liu B, et al
    Improved breast cancer histological grading using deep learning.
    Ann Oncol. 2021 Sep 29. pii: S0923-7534(21)04486.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.